Wegovy mg Levels: What the Dose Schedule Actually Means

The myth that a higher mg level always means faster results

The most persistent misunderstanding about Wegovy's mg levels is that patients should push toward the highest dose as quickly as possible. It's understandable, if 2.4 mg produces more weight loss than 0.5 mg, surely getting there in two weeks beats getting there in twenty? The evidence says otherwise.

The graduated schedule exists primarily to protect your digestive system. Semaglutide slows gastric emptying and reduces appetite through GLP-1 receptor activation; introduce too much too soon and the result is significant nausea, vomiting, and the kind of GI disruption that leads people to stop treatment altogether. The NHS guidance on semaglutide makes clear that the titration steps are not optional milestones to be rushed through.

Clinically, the body also adapts to each level before the next is introduced. Spending the prescribed time at each dose gives your appetite-regulation system time to recalibrate, which tends to produce steadier, more sustainable progress than aggressive early escalation. Your prescriber decides when (and whether) to move up, taking into account tolerability, your starting weight, and any other health factors. That decision belongs with them, not with an app or a peer-reviewed article you found at midnight.

What actually happens at each mg level

The 0.25 mg weekly dose is the foundation of the schedule. Think of it as the adjustment period: its job is to let your system settle, not to drive weight change. Most people notice very little in terms of appetite suppression at this level, which is entirely expected.

From 0.5 mg through 1.7 mg, appetite suppression tends to build progressively. Some people respond well enough at 1.7 mg that moving to full maintenance isn't clinically necessary; others move through these steps without significant side effects and tolerate the transition to maintenance dose smoothly. There is no single right experience.

The 2.4 mg weekly dose has been the standard maintenance level since Wegovy's original UK licence, and it is the dose underpinning the STEP 1 trial data: an average body-weight reduction of around 15% over 68 weeks, published in the New England Journal of Medicine. That figure is a population average from clinical trial conditions, individual results vary considerably.

The 7.2 mg level is the newest addition. On 14 April 2026 the MHRA approved a dedicated single-dose pen at this strength, designed for adults with a BMI of 30 or above. If you want a detailed breakdown of how each Wegovy mg strength is structured and what distinguishes one from another, that page covers the full picture. Trial data at 7.2 mg reported around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide's trial results. Crucially, the starting point remains 0.25 mg regardless of which maintenance dose you eventually reach, there is no shortcut into the higher tier. If you want to understand how the full Wegovy dose options compare in practice, that page goes into more detail on each level's clinical context.

Staying on a dose for longer than planned, when that's the right call

Prescribers sometimes extend the time at a given mg level when side effects are significant or when a patient is managing other health factors alongside treatment. This is sound practice, not failure.

The published schedule describes the minimum time at each step; it sets no ceiling. Someone who finds 1.0 mg producing marked nausea can legitimately remain there for eight weeks rather than four, with their prescriber's agreement, then attempt 1.7 mg when symptoms have settled. The pen itself doesn't care about the calendar. Keep it in the fridge door alongside anything else that needs refrigerating, take it on the same day each week, and let the schedule breathe where it needs to.

If you are transferring from another provider and arrive mid-titration, your prescriber will want evidence of your current dose and how long you have been on it before confirming the next step. That is standard clinical practice, not obstruction. You can find a broader overview of what the dosage levels for Wegovy are and what influences titration decisions in the Wegovy dosage levels guide.

One detail worth noting: the 7.2 mg pen is licensed for weight management only, not for the cardiovascular indication that Wegovy also holds. If your treatment is for weight management under the weight-loss licence, that distinction is handled at the clinical assessment stage. For those who want to see dose progression set out visually, the Wegovy dose levels chart maps the timeline clearly.

Private access versus the NHS, and where mg levels fit into that

On the NHS, Wegovy is available through specialist weight management services under NICE guidance (TA875), subject to eligibility criteria and, in practice, long waiting lists in many areas. The titration schedule is the same regardless of route; what differs is the clinical team managing it and how quickly you can access the medicine in the first place.

Through a private, GPhC-registered online pharmacy, you can begin the consultation process without a referral or wait. The prescriber still assesses you fully (weight, medical history, current medicines, contraindications) and the same titration principles apply. Anyone curious about how the dosage levels of Wegovy are structured and why each step is set where it is will find that covered in detail on that page. There is no version of Wegovy that skips the 0.25 mg starting point because a patient is keen to reach 7.2 mg sooner. If cost context is useful as you weigh up your options, the weight loss treatment overview covers what private treatment includes and how pricing tends to be structured. Private prescription doesn't mean cutting corners on the clinical process; it means a prescriber, not a waiting list, is the gating factor.

A real clinician reads your consultation the same day at nume, not software routing you to a template response. Patients sometimes also ask whether semaglutide affects estrogen levels, and that question is addressed in full for anyone for whom hormonal considerations are relevant. You can also read more about the team behind that process on the clinical team page. Side effects from any semaglutide dose, or any concerns mid-treatment, can be reported directly via the MHRA Yellow Card scheme.